Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing medicines to enhance the life of cancer patients. Its product in development include VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibitor that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
IPO Year: 2012
Exchange: NASDAQ
Website: verastem.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/16/2025 | Overweight | Cantor Fitzgerald | |
| 4/10/2025 | $15.00 | Buy | Jefferies |
| 3/24/2025 | $7.00 → $10.00 | Buy | H.C. Wainwright |
| 12/31/2024 | $13.00 → $20.00 | Buy | BTIG Research |
| 9/30/2024 | $13.00 | Buy | Guggenheim |
| 11/21/2023 | $27.00 | Buy | BTIG Research |
| 9/27/2023 | $21.00 | Buy | B. Riley Securities |
| 6/15/2023 | $24.00 → $36.00 | Neutral → Buy | Mizuho |
| 9/7/2022 | $6.00 | Buy | Alliance Global Partners |
| 4/29/2022 | $6.00 → $5.00 | Overweight | Cantor Fitzgerald |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Cantor Fitzgerald resumed coverage of Verastem with a rating of Overweight
Jefferies initiated coverage of Verastem with a rating of Buy and set a new price target of $15.00
H.C. Wainwright reiterated coverage of Verastem with a rating of Buy and set a new price target of $10.00 from $7.00 previously
BTIG Research reiterated coverage of Verastem with a rating of Buy and set a new price target of $20.00 from $13.00 previously
Guggenheim initiated coverage of Verastem with a rating of Buy and set a new price target of $13.00
BTIG Research resumed coverage of Verastem with a rating of Buy and set a new price target of $27.00
B. Riley Securities initiated coverage of Verastem with a rating of Buy and set a new price target of $21.00
Mizuho upgraded Verastem from Neutral to Buy and set a new price target of $36.00 from $24.00 previously
Alliance Global Partners resumed coverage of Verastem with a rating of Buy and set a new price target of $6.00
Cantor Fitzgerald resumed coverage of Verastem with a rating of Overweight and set a new price target of $5.00 from $6.00 previously
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Verastem, Inc. (0001526119) (Issuer)
4 - Verastem, Inc. (0001526119) (Issuer)
4 - Verastem, Inc. (0001526119) (Issuer)
4 - Verastem, Inc. (0001526119) (Issuer)
4 - Verastem, Inc. (0001526119) (Issuer)
4 - Verastem, Inc. (0001526119) (Issuer)
4 - Verastem, Inc. (0001526119) (Issuer)
4 - Verastem, Inc. (0001526119) (Issuer)
4 - Verastem, Inc. (0001526119) (Issuer)
4 - Verastem, Inc. (0001526119) (Issuer)
S-8 - Verastem, Inc. (0001526119) (Filer)
10-Q - Verastem, Inc. (0001526119) (Filer)
8-K - Verastem, Inc. (0001526119) (Filer)
8-K - Verastem, Inc. (0001526119) (Filer)
8-K - Verastem, Inc. (0001526119) (Filer)
8-K - Verastem, Inc. (0001526119) (Filer)
EFFECT - Verastem, Inc. (0001526119) (Filer)
SCHEDULE 13G/A - Verastem, Inc. (0001526119) (Subject)
SCHEDULE 13G/A - Verastem, Inc. (0001526119) (Subject)
SCHEDULE 13G/A - Verastem, Inc. (0001526119) (Subject)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Verastem, Inc. (0001526119) (Issuer)
Fastest customizable press release news feed in the world
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate and present at the following investor conferences in November: Guggenheim Healthcare Conference 2025: Fireside chat on Tuesday, November 11 at 1:00 pm ET Jefferies Global Healthcare Conference in London: Fireside chat on Wednesday, November 19 at 2:30 pm GMT (9:30 am ET) A live webcast of the fireside chats can be accessed under "Events & Presentations" in the Investor section of the Company's website, https://investor.verastem.com/events. A replay of the webcasts will b
Achieved AVMAPKI™ FAKZYNJA™ CO-PACK net product revenue of $11.2 million VS-7375 cleared first two monotherapy dose levels with no dose-limiting toxicities reported; no nausea, vomiting or diarrhea greater than Grade 1 were observed Enrollment initiated for VS-7375 in combination with cetuximab in patients with advanced KRAS G12D mutant solid tumors, including colorectal cancer Ended Q3 2025 with $137.7 million in cash and cash equivalents; with expected product revenue and exercise of cash warrants, Company cash runway would extend into the second half of 2026 Company to host a conference call and webcast today at 8:00 a.m. ET Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical compa
First two monotherapy dose levels (400 mg QD and 600 mg QD) cleared, with no dose-limiting toxicities reported Promising anti-tumor activity observed in patients with various solid tumors, including advanced pancreatic ductal adenocarcinoma No nausea, vomiting, or diarrhea greater than Grade 1 was observed Enrollment initiated for VS-7375 in combination with cetuximab in patients with advanced KRAS G12D mutant solid tumors, including colorectal cancer Plan to report an interim safety and efficacy update on the Phase 1/2a trial in the first half of 2026 Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK-pathw
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its third quarter 2025 financial results and business updates on Tuesday, November 4, 2025, at 8:00 am ET. To access the conference call, please dial (888) 596-4144 (U.S.) or (646) 968-2525 (international) and enter the passcode 8194537 at least 10 minutes prior to the event start time. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, https://inv
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of stock options to purchase 138,000 shares of its common stock to nine new employees. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee's acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price equal to $8.80 per share, the closing price of Verastem Oncology's common stock as reported by Nasdaq on October 1, 2025. The stock options to purchase 118,000 shares of common st
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate and present at the following investor conferences in September: Cantor Global Healthcare Conference 2025: Fireside chat on Wednesday, September 3 at 3:55 pm ET H.C. Wainwright 27th Annual Global Investment Conference: Fireside chat on Monday, September 8 at 12:00 pm ET A live webcast of the fireside chats can be accessed under "Events & Presentations" in the Investor section of the Company's website, https://investor.verastem.com/events. A replay of the webcasts will
GFH375 demonstrated an overall response rate (ORR) of 68.8% in non-small cell lung cancer (NSCLC) at the recommended Phase 2 dose of 600 mg QD GFH375 demonstrated an ORR of 57.7% in efficacy evaluable patients with NSCLC across all dose levels Mini oral presentation on Sunday, September 7, 2025 from 12:00 to 1:15 pm (CEST) Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK-pathway-driven cancers, today announced positive, updated safety and efficacy data and late-breaking presentation details of partner GenFleet Therapeutics' Phase 1/2 study in China of GFH375, an oral KRAS G12D (ON/OFF) inhibitor, known as VS-7
Achieved AVMAPKI™ FAKZYNJA™ CO-PACK net product revenue of $2.1 million in the first six weeks of launch First patient dosed in the U.S. trial for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, in KRAS G12D advanced solid tumors Ended Q2 2025 with $164.3 million in cash and cash equivalents; with product revenue and exercise of cash warrants, Company has expected cash runway into the second half of 2026 Company to host a conference call and webcast today at 4:30 p.m. ET Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced business updates and reported financial results for
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its second quarter 2025 financial results and business updates on Thursday, August 7, 2025, at 4:30 pm ET. To access the conference call, please dial (800) 715-9871 (U.S.) or (646) 307-1963 (international) and enter the passcode 1210516 at least 10 minutes prior to the event start time. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, https://inv
Enrollment is ongoing in U.S. Phase 1/2a trial for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, in KRAS G12D advanced solid tumors KRAS G12D mutation is the most prevalent KRAS mutation in human cancers and 37% of pancreatic cancers harbor a KRAS G12D mutation Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, for the first-line treatment of patients with KRAS G12D-mutated locally advanced or metastatic adenocarcinoma of the pancreas (PDAC)
This live feed shows all institutional transactions in real time.
SC 13G/A - Verastem, Inc. (0001526119) (Subject)
SC 13G/A - Verastem, Inc. (0001526119) (Subject)
SC 13G - Verastem, Inc. (0001526119) (Subject)
SC 13G/A - Verastem, Inc. (0001526119) (Subject)
SC 13G/A - Verastem, Inc. (0001526119) (Subject)
SC 13G/A - Verastem, Inc. (0001526119) (Subject)
SC 13G/A - Verastem, Inc. (0001526119) (Subject)
SC 13G/A - Verastem, Inc. (0001526119) (Subject)
SC 13G - Verastem, Inc. (0001526119) (Subject)
SC 13G/A - Verastem, Inc. (0001526119) (Subject)
Live finance-specific insights
Achieved AVMAPKI™ FAKZYNJA™ CO-PACK net product revenue of $11.2 million VS-7375 cleared first two monotherapy dose levels with no dose-limiting toxicities reported; no nausea, vomiting or diarrhea greater than Grade 1 were observed Enrollment initiated for VS-7375 in combination with cetuximab in patients with advanced KRAS G12D mutant solid tumors, including colorectal cancer Ended Q3 2025 with $137.7 million in cash and cash equivalents; with expected product revenue and exercise of cash warrants, Company cash runway would extend into the second half of 2026 Company to host a conference call and webcast today at 8:00 a.m. ET Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical compa
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its third quarter 2025 financial results and business updates on Tuesday, November 4, 2025, at 8:00 am ET. To access the conference call, please dial (888) 596-4144 (U.S.) or (646) 968-2525 (international) and enter the passcode 8194537 at least 10 minutes prior to the event start time. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, https://inv
Achieved AVMAPKI™ FAKZYNJA™ CO-PACK net product revenue of $2.1 million in the first six weeks of launch First patient dosed in the U.S. trial for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, in KRAS G12D advanced solid tumors Ended Q2 2025 with $164.3 million in cash and cash equivalents; with product revenue and exercise of cash warrants, Company has expected cash runway into the second half of 2026 Company to host a conference call and webcast today at 4:30 p.m. ET Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced business updates and reported financial results for
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its second quarter 2025 financial results and business updates on Thursday, August 7, 2025, at 4:30 pm ET. To access the conference call, please dial (800) 715-9871 (U.S.) or (646) 307-1963 (international) and enter the passcode 1210516 at least 10 minutes prior to the event start time. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, https://inv
AVMAPKI plus FAKZYNJA to be commercially available by prescription as a convenient oral combination co-packaged together and will be known as "AVMAPKI FAKZYNJA CO-PACK" Accelerated approval, well ahead of the June 30, 2025 PDUFA action date, was based on the Phase 2 RAMP 201 study that demonstrated a 44% overall response rate in patients with KRAS mutant recurrent LGSOC Verastem to host investor conference call and webcast today at 2:30 pm ET Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the U.S. Food and Drug Administration (FDA) has approved AVMAPKI™ FAKZYNJA™ CO-
Robust overall response rates observed (31% overall, 44% in KRAS mutant, 17% in KRAS wild-type) in patients whose cancer had progressed despite prior treatment with chemotherapy and/or MEK inhibitors and/or bevacizumab Patients on avutometinib and defactinib achieved a median progression free survival of more than one year (12.9 months); 22 months in KRAS mutant population The Company recently met with the FDA to review the mature data set and remains on track to complete the NDA submission in October 2024 Additional data to be presented at the IGCS meeting and during Company-hosted investor conference call and webcast today, October 17, 2024 at 4:30 pm EDT Verastem Oncology (NASDAQ:VST
Company to host investor conference call and webcast on October 17, 2024, at 4:30 pm EDT Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced further details for its late-breaking presentation of mature data from the ongoing Phase 2 RAMP 201 (ENGOT-ov60/GOG-3052) clinical trial to be presented as an oral presentation at a plenary session at the International Gynecologic Cancer Society (IGCS) Annual Global Meeting taking place October 16-18, 2024 in Dublin, Ireland. The late-breaking abstract is embargoed until the morning of the presentation at IGCS. The oral presentation will include updated safety and
Plan to complete NDA submission with the mature RAMP 201 dataset, anticipated to include 12 months of follow-up, in the second half of 2024 Plan to present the mature dataset from RAMP 201 at a medical conference in the second half of 2024 Avutometinib and defactinib combination have continued to show robust and durable response rates in ongoing RAMP 201 trial in patients with recurrent low-grade serous ovarian cancer Company to host investor conference call and webcast on Friday, May 24, 2024 at 8:00 am EDT to provide update on RAMP 201 and rolling NDA submission Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with canc
83% (5/6) of patients achieved a confirmed partial response in cohort 1, the most mature dose level; one dose-limiting toxicity was observed, however, the dose level was subsequently cleared after additional patients were enrolled Follow up of patients in the additional dose and schedule cohorts is ongoing to determine the recommended Phase 2 dose for study expansion Poster presentation on Saturday, June 1, 2024 at the ASCO Annual Meeting Company to host investor conference call and webcast on Friday, May 24, 2024 at 8:00 am EDT to discuss these data Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today ann
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it has entered into a definitive agreement to sell approximately 2.1 million shares of its Series B Convertible Preferred Stock (the "Preferred Stock") to affiliates of BVF Partners L.P. in a private placement to raise aggregate gross proceeds of up to approximately $60 million in two tranches, before deducting fees to the placement agent and other estimated offering expenses payable by the Company. The initial tranche, consisting of 1.2 million shares of Preferred Stock for gross proceeds of approximately $30 million, representing a purchase price
Live Leadership Updates
Avutometinib plus defactinib granted priority review by FDA in December 2024, under the accelerated approval pathway, for KRAS mutant recurrent LGSOC; PDUFA action date set for June 30, 2025 Filed an investigational new drug application in the U.S. for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor RAMP 205 trial in 1L metastatic pancreatic cancer continues to progress with an additional dose cohort added and enrollment across all dose-level cohorts on track to complete in Q1 Company cash, cash equivalents, and investments of $88.8 million as of December 31, 2024; pro forma $151.3 million including debt refinancing and equity issuance with Oberland, and equity issuance under at-the-market
New executive leadership supports the company's transition to a fully integrated commercial-stage organization in a year of transformative growth with a potential new product launch in mid-2025. Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Matthew E. Ros as chief operating officer. In his role, Mr. Ros will report to Dan Paterson, president and chief executive officer, and will serve on the company's executive leadership team. "We are thrilled to welcome Matt to Verastem Oncology at an important time as we prepare for a mid-2025 product launch and th
Shoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer Announces Business Updates NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the following leadership changes, effective immediately: John H. Johnson, a recognized leader in the pharmaceutical and biotechnology industry, has been named Executive Chairman;Dr. Shoshana Shendelman has stepped down as Chair and CEO; andLes Funtleyder, Applied Therapeutics' Chief Financial Officer, has been named Interim Chief Executive Officer. Mr. John
Plan to announce topline RAMP 201 data with the start of planned rolling NDA submission for avutometinib and defactinib combination in recurrent low-grade serous ovarian cancer in Q2 2024 FDA Fast Track Designation granted for avutometinib in combination with adagrasib for the treatment of KRAS G12C-mutated metastatic non-small cell lung cancer FDA Fast Track Designation granted for avutometinib plus defactinib in combination with sotorasib for the treatment of KRAS G12C-mutated metastatic non-small cell lung cancer Initial safety and efficacy results from the RAMP 205 trial of avutometinib and defactinib in combination with current standard of care in first-line metastatic pancreatic
Dr. Hayslip to lead development programs for avutometinib, including Verastem Oncology's international confirmatory Phase 3 RAMP 301 clinical trial, and advance pipeline assets Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of John Hayslip, M.D., an accomplished oncologist with deep clinical research, development, and commercialization experience, to chief medical officer where he will lead the Company's clinical and medical strategy. Dr. Hayslip succeeds Louis J. Denis, M.D., who recently departed the company. "John is a recognized leader in oncology with broad expertise across
Brian Stuglik to Retire from CEO Role; Continue to Serve on Company's Board of Directors Verastem Oncology (NASDAQ:VSTM) (the "Company"), a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced today that Dan Paterson, President and Chief Operating Officer, has been promoted to President and Chief Executive Officer (CEO). Brian Stuglik will retire from the CEO role and remain a member of the Board of Directors. These changes will be effective August 1, 2023, allowing for a smooth leadership transition. "On behalf of the Board of Directors, I would like to thank Brian for his leadership during which the Company emerged as a recognized innovato
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of Karin Tollefson to its Board of Directors, effective May 15, 2023. Dr. Tollefson is the Senior Vice President and Head of Global Medical Affairs at Seagen Inc. where she has led the medical organization through the successful launches of three practice-changing medicines and established a global medical affairs organization. "Karin's deep oncology and pharmaceutical experience and her work bringing groundbreaking new medicines to patients will be important as Verastem moves from late-stage development to commercial preparation," sai
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of Robert Gagnon to its Board of Directors, effective December 13, 2022. Mr. Gagnon is the Chief Financial Officer and Operating Partner at Gurnet Point Capital, a healthcare venture capital and private equity fund and the former Chief Business Officer and Chief Financial Officer at Verastem Oncology. "Rob's expertise in all areas of biopharmaceutical finance, including his ability to navigate complex business challenges, combined with his deep understanding of Verastem's goals and operations, will be invaluable to Verastem's work," sai
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of Anil Kapur to its Board of Directors, effective October 20, 2022. Mr. Kapur is the Executive Vice President, Corporate Strategy and Chief Commercial Officer at Geron Corporation. "Anil's deep experience in oncology and his track record of product launch and commercial operations excellence will be invaluable as Verastem works to bring its lead compound RAF/MEK clamp VS-6766 in combinations across RAS-driven tumors to patients," said Michael Kauffman, M.D., Ph.D., Lead Director of the Verastem Oncology Board of Directors. "I am please
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the appointment of Michelle Robertson to its Board of Directors, effective November 15, 2021. Ms. Robertson, who is the Chief Financial Officer at Editas Medicine, will chair the audit committee. She will fill a vacancy created by Gina Consylman, who is stepping down from the Board later this year to focus on other professional duties. "We are immensely appreciative of Gina's many important contributions to Verastem during her tenure on the Board, and we look forward to welcoming Michelle as Verastem continues to rapidly advance its development pro